BioCatalyst

zenocutuzumab (MCLA-128) — catalyst calendar

1 verified catalyst event(s) referencing zenocutuzumab (MCLA-128), each linked to its official source. Verified as of 2026-09-20.

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-12-31
in 3mo
ESTIMATED
 READOUT
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an N
Phase 2 · Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion
 Partner Therapeutics, Inc. zenocutuzumab (MCLA-128) ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.